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Abstract
DNA viruses, retroviruses and hepadnaviruses, such as hepatitis B virus (HBV), are vulnerable to genetic editing of single
stranded DNA by host cell APOBEC3 (A3) cytidine deaminases. At least three A3 genes are up regulated by interferon-a in
human hepatocytes while ectopic expression of activation induced deaminase (AICDA), an A3 paralog, has been noted in a
variety of chronic inflammatory syndromes including hepatitis C virus infection. Yet virtually all studies of HBV editing have
confined themselves to analyses of virions from culture supernatants or serum where the frequency of edited genomes is
generally low (#10
22). We decided to look at the nature and frequency of HBV editing in cirrhotic samples taken during





+) as well as 4 normal livers were studied. Compared to normal liver, 5/7 APOBEC3 genes were significantly up
regulated in the order: HCV6HBV.HBV.alcoholic cirrhosis. A3C and A3D were up regulated for all groups while the
interferon inducible A3G was over expressed in virus associated cirrhosis, as was AICDA in ,50% of these HBV/HCV samples.
While AICDA can indeed edit HBV DNA ex vivo, A3G is the dominant deaminase in vivo with up to 35% of HBV genomes
being edited. Despite these highly deleterious mutant spectra, a small fraction of genomes survive and contribute to loss of
HBeAg antigenemia and possibly HBsAg immune escape. In conclusion, the cytokine storm associated with chronic
inflammatory responses to HBV and HCV clearly up regulates a number of A3 genes with A3G clearly being a major
restriction factor for HBV. Although the mutant spectrum resulting from A3 editing is highly deleterious, a very small part,
notably the lightly edited genomes, might help the virus evolve and even escape immune responses.
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Introduction
The human genome harbours a group of 11 genes encoding
cytidine deaminases, the majority having substrate specificity for
single stranded DNA (ssDNA) [1,2,3,4,5,6,7,8,9,10]. These
include the prototypical enzyme APOBEC1 (A1) and activation
induced deaminase (AICDA). The large seven gene APOBEC3
cluster spans ,150kb at ch22q13.1 [11]. Two additional genes,
APOBEC2 and APOBEC4, show homology to the above, although
no editing activity has been described so far for either. Many of the
human APOBEC3 (A3) enzymes can edit the cDNA of numerous
retroviruses, retrovirus elements and hepadnaviruses in tissue
culture experiments [3,4,6,12,13,14,15,16,17,18,19,20,21]. Yet in
vivo only the lentiviruses, of which human immunodeficiency virus
(HIV) is the most notorious, hepatitis B virus (HBV), human
papillomaviruses (HPV) and TTV genomes have proven to be
edited [21,22,23,24,25,26,27].
The outcome of cytidine deamination is oxidation of the C4
amino group yielding uridine - in short cytidine deamination is
mutagenic. The degree of editing can be as little as a few bases per
kilobase or up to 90% of all cytidine residues, APOBEC3A
deamination of hepatitis B virus DNA in tissue culture being a case
in point [16]. In virology, mutations are generally related to the
plus strand. Hence, so called GRA hypermutants reflect cytidine
deamination of (2) stand DNA while CRT hypermutants reflect
editing of the viral (+) strand. Due to the extent of editing,
hypermutation can be seen as part of an innate anti-viral response.
This theme is echoed by the fact that some APOBEC3 genes are up
regulated by interferon-a and –c in a wide variety of cells
including primary human hepatocytes [28,29,30,31,32,33,34,35].
While AICDA expression is chiefly expressed in germinal centre
centroblasts [36], ectopic expression of human AICDA has been
shown in at least four settings, all involving chronic inflammation –
HCV associated chronic hepatitis, Helicobacter pylori associated
stomach cancer, human colitis and chronic inflammatory bile duct
disease [37,38,39,40,41]. Transgenic mice bearing the human
AICDA or A1 genes invariably induce cancers, the organ specificity
being dependent on the promoter [42,43,44]. As there is a long
historical link between chronic inflammation and cancer [45,46],
the ensemble suggested a link between aberrant AICDA expression
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editing of the nuclear genome [41,44,47]. Cancer frequently
emerges from a background of cellular dysplasia. For the liver,
cirrhosis is seen as a polyclonal proliferative disease, a prodrome
that generally precedes the HCC. Yet virtually all APOBEC
editing studies of the HBV genome have confined themselves to
analyses of virions from culture supernatants or serum where the
frequency of edited genomes is generally low (#10
22, [21,25]). In
view of the above observations, we decided to look at the nature
and frequency of HBV editing in cirrhotic liver samples taken
during removal of a primary HCC. Given the finding of ectopic
AICDA expression in HCV associated chronic hepatitis [39,48], we
chose to work with cirrhotic tissue from HBV mono- and HBV
plus HCV double infections.
It is shown here that while human AICDA can indeed hyperedit
HBV genomes in an in vitro setting, editing by AICDA is a rare
event in vivo. By contrast, up to 35% of HBV genomes are edited in
vivo by several A3 enzymes including A3G indicating that human
A3 deaminases represent major restriction factors for HBV
replication. Yet through HBV editing, A3 deaminases generate a
mutant spectrum upon which selection can occur. It is suggested
that APOBEC3 editing may contribute towards loss of HBeAg
antigenemia and immune escape.
Results
Up regulation of APOBEC deaminases in cirrhosis
A succinct description of the 41 cirrhotic samples is given in
Table S1. Ten DNA samples from patients with alcoholic
cirrhosis, 10 HBV
+,1 1H B V
+HCV
+ and 10 from HCV
+
patients were analysed. Complementary DNA was made to total
RNA extracted in parallel with the DNA samples and
hybridized to a custom made TaqMan PCR chip comprising
all 11 human cytidine deaminases related genes (A1, A2, A3A–H,
A4 and AICDA), a number of pro-inflammatory, apoptotic and
mismatch repair genes as well as 3 reference genes (TRIM44,
HMBS and LMF2) that have been validated for analyses of liver
tissue.
Compared to the 4 normal livers, there was significant up
regulation of 2–5 A3 genes in the order: HCV6HBV.HBV.al-
coholic cirrhosis. A3C and A3D were up regulated for all groups,
while the interferon inducible A3G was over expressed in virus
associated, as opposed to alcoholic cirrhosis (Figure 1, Figure S1 &
Table S2). While there was a trend towards increased A3A and
A3F expression in all four groups, it never reached statistical
significance. AICDA was up regulated in 15/31 HBV and/or HCV
samples, indicating that ectopic expression of AICDA is also a
feature of HBV liver disease (Figure 1 inset). By contrast
expression was undetectable in the normal liver, which is why
the data are not normalized as per A3 data (Figure S1). APOBEC1
was phenomenally expressed in one sample (#146) yet again
normalization wasn’t possible as it was weakly expressed in just
one normal liver sample (Figure 1 inset). APOBEC2 transcripts
Author Summary
Retroviruses and hepadnaviruses such as hepatitis B virus
(HBV) are vulnerable to mutation by host cell single
stranded DNA cytidine deaminases. The result is hypermu-
tated viral peppered with uracil residues. While there are
potentially 11 such human enzymes, the major players
belong to the 7 gene APOBEC3 cluster on chromosome 22,
some of which can be activated by anti-viral interferons.
We investigated the nature and frequency of HBV editing
in 41 cirrhotic samples following surgical removal of
primary hepatocellular carcinoma. Numerous APOBEC3
genes were activated in the decreasing order
HCV6HBV.HBV.alcoholic cirrhosis. We observed that
APOBEC3G was the dominant restricting factor in vivo with
up to 35% of HBV edited genomes. Among the HBV
mutants generated by APOBEC3 editing, we found a small
fraction of lightly APOBEC3G edited genomes that can
impact HBV replication in vivo and possibly immune
escape.
Figure 1. Transcription profiling of all 11 human cytidine deaminases in cirrhosis. The A3 transcription data are in the form of box-whisker
plots with the mean, quartiles, maxima and minima. Data are normalized to the expression levels of three invariable reference genes (TRIM44, HMBS
and LMF2). Asterisks indicate statistically significant up regulation: ** 0.01,p,0.001; * 0.05,p,0.01. Inset) AICDA, APOBEC1 and APOBEC2 transcripts
were detected in 0, 1 and 1 HL samples respectively but present in several HBV6HCV samples. APOBEC4 transcripts were undetectable in all samples
tested.
doi:10.1371/journal.ppat.1000928.g001
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out. A number of cellular genes associated with inflammation were
significantly up regulated, notably FAS, FASLG, BCL2, IFNc and
LTA (Table S2).
AICDA can hyperedit HBV genomes ex vivo
An infectious molecular clone of HBV was transfected into the
hepatocyte derived Huh7 cell line along with human AICDA
construct and A3G as positive control. HBsAg secretion in the
supernatant was used as readout for editing at a macroscopic level.
Figure 2A shows that both AICDA and A3G expression reduced
HBsAg to levels #50% of control. Given that transfection
frequencies were ,30–40%, this suggests that the majority of
genomes were edited. At 72 hours, total DNA was recovered from
the supernatants and 3DPCR performed on a segment of the X
gene [16,21,49,50]. 3DPCR products were recovered as low as
85.2uC for the AICDA cotransfection compared to 86.6uC for the
A3G control (Figure 2B). The 88.7uC 3DPCR products were
cloned and sequenced. As can be seen from the mutation matrices
(Figure 2C), AICDA (mean cytidine deamination frequency,
fc=42%, range 16–61%) was just as good as A3G at hyperediting
HBV DNA (fc=33%, range 7–98%).
As expected from extant data, AICDA editing of the HBV
target was concentrated in GpC and ApC sites [1,51] unlike its A3
counterparts (Figure 2D). Combined with previous data we now
have a reference set for the HBV X region edited by 8/11 human
cytidine deaminases [16]. Four deaminases (A3G, A3H, A1 and
AICDA) showed polarized editing biases (Figure 2D) that can be
used as hallmarks for specific deaminase activity in vivo. The
singularity of AICDA and A3G editing with respect to other A3
enzymes becomes apparent when plotting the number of edited
cytidine residues in selected dinucleotide contexts for single
sequences (Figures 2E).
A3G and not AICDA is the major restriction factor in vivo
With these metrics in hand, 3DPCR was used to identify
hyperedited HBV genomes from the cirrhotic samples. First round
PCR DNA was performed on ,0.5mg of total DNA using the X
gene specific primers. In a second round, 3DPCR was performed
at the restricting temperature of 88.7uC (Figure 3A). Fifteen of 17
DNA samples (88%) yielded robust amplification at the restrictive
temperature. Five DNA samples – 2 HBV and 3 HBV+HCV -
indicated by asterisks were cloned and sequenced. Hyperediting of
the HBV genome was essentially confined to the minus DNA
Figure 2. AICDA impacts HBV replication by hyperediting the genome. A) Macroscopic impact of AICDA and A3G on HBsAg secretion into
the culture supernatant following transfection of the infectious molecular clone, pCayw. B) 3DPCR recovered A3G- and AICDA-edited HBV genomes
down to 86.6uC and 85.2uC respectively. pv: empty plasmid vector and HBV alone. Asterisks refer to the samples cloned and sequenced. C) Mutation
matrices for hyperedited X gene sequences derived from cloned 88.7uC 3DPCR products. n indicates the number of bases sequenced. D) Bulk
dinucleotide context of HBV X region minus strand DNA by eight human cytidine deaminases. E) Clonal analysis of editing for individual edited
sequences. The number of TpC+CpC vs. GpC+ApC targets edited per sequence are computed and represented on the y and x axes respectively. As
the A3C and A3G genes were strongly up regulated (Figure 1) they have been separated from the others. Clonal analysis using TpC vs. CpC allows
clear isolation of A3G from other A3 enzymes.
doi:10.1371/journal.ppat.1000928.g002
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in keeping with previous reports [21]. The mean cytidine editing
frequencies were somewhat higher in the case of HCV co-
infections (fc=38.8%, 41.7% and 46.9%) compared to HBV
monoinfection (fc=23.3% and 31.6%, Figure 3B).
The dinucleotide editing context for these hyperedited genomes
was remarkably uniform with a strong preference for CpC and an
aversion for ApC, which fits rather well with the profile for A3G
(not shown). However, it is possible that such averaging could
mask the occasional AICDA edited genome. Accordingly, a clonal
analysis was used to highlight editing by distinct enzymes
(Figure 3C). Very few patient sequences mapped to the area
characteristic of AICDA (Figure 3C. vs. Figure 2E), indicating that
it is not a major editor in vivo. By contrast, between 57–71% of
patient sequences fell within the area covered by A3G (Figure 3D
vs. Figure 2E). The remaining sequences mapped to regions where
there was considerable overlap between A3 deaminases
(Figure 2E). As A3C was significantly up regulated in these liver
samples and expressed at greater levels than any other A3 gene
(Figure 1), editing by A3C alone could explain the remainder.
In order to determine accurately the overall hyperediting
frequencies in vivo, we performed deep sequencing on cloned first
round PCR DNA (95uC). To our surprise for 4/5 samples a
sizeable proportion (10–35%) of X gene segments showed
unmistakable signs of hyperediting. The frequency distribution
of editing is shown in Figure 4A. Some sequences harboured up to
50/58 (86%) edited cytidines (Figure 4A inset), comparable to
those recovered from a transfection experiment. Figure 4B shows
the frequency distribution of hyperedited genomes from patients
recovered by 3DPCR. That the two frequency distributions are
distinct reflects selection against lightly edited genomes during
3DPCR, as previously noted [21]. For the 95uC derived
sequences, dinucleotide and clonal analysis indicated that the
edited bases showed the same hallmarks as those recovered by
3DPCR, that is a penchant for CpC typical of A3G editing with at
least one other A3 enzyme explaining the remainder (Figure 4C–
E). Hence, Figure 4B represents a subset of a more general
distribution typified by Figure 4A.
Assuming that the highly edited part of the distribution (n$18,
Figure 4B) is unaffected by suboptimal amplification, then the
expected number of edited genomes can be calculated to be
300679/7=3386 (see legend to Figure 4). In other words ,12
fold more genomes are edited than suggested by 3DPCR. Yet the
actual number is probably higher as the X gene segment analyzed
Figure 3. A3 deaminases are the major editors of HBV DNA in vivo. A) PCR and 3DPCR amplification at the normal and restrictive
temperatures of 95uC and 88.7uC respectively. Sample codes are given above. Five 3DPCR samples identified by asterisks were chosen for cloning and
sequencing. B) Summary of the unique hyperedited sequences in the form of the number and fraction of GRA (minus stand) edits, CRT (plus strand)
and all other point mutations. The excess of GCRAT transitions over all other mutations varied from 23–40 fold. C) Clonal analysis using the number
of TpC+CpC vs. GpC+ApC targets edited. The vast majority of patient sequences map to the area typical of APOBEC deaminases. D) Clonal analysis
using the number of TpC vs. CpC targets edited. The majority of sequences map to the area typical of APOBEC3G (between 57–71% marked in bold
face).
doi:10.1371/journal.ppat.1000928.g003
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type X gene sequence could be edited elsewhere. Hence, the real
frequencies of slightly edited genomes are almost certainly higher.
A subset of A3 edited genomes can be repaired
A sizeable proportion of neo-synthesized HBV DNA returns to
the nucleus to augment the pool of cccDNA, the viral replication
template. DNA bearing multiple dU residues might be degraded
by the UNG-APE1 pathway or, if copied on the opposite strand,
the resulting dU(2):dA(+) base pair might be corrected to dT:dA.
To explore this issue we performed first round and 3DPCR on
sample #326 using Pfu polymerase. Like all archaeal DNA
polymerases, Pfu is unable to amplify DNA templates bearing dU
[52]. As can be seen, Pfu amplification recovered much less
hyperedited DNA than Taq polymerase (Figure 4F). There were
enough 3DPCR products from the 88.7uC amplification to allow
cloning and sequencing. The genomes were exclusively edited on
the minus strand (mean fc=25%, Figure 4G) indicating that
multiple dU:dA pairs can be repaired to dT:dA. The correspond-
ing amplification using Taq (Figure 4G) yielded a comparable
frequency (fc=32%). These observations indicate that substantial
repair does occur for a small number of hyperedited genomes.
Precore/core mutations
The HBV core orf allows translation from the first, suboptimal
AUG giving rise to the HBeAg precursor. Serum HBeAg is a
Figure 4. High frequency of A3 editing recovered by standard PCR. A) Frequency analysis of edited genomes as a function of the number of
edits per sequence for 95uC derived PCR products. The 268 bp sequences were derived from the first round product. The sequences in insert to
Figure 4A were stripped down to the size of the inner 167 bp locus and reanalyzed to allow comparison with the 3DPCR products. The numbers
above the columns indicate the combined numbers of sequences across the four samples. B) Frequency distribution of edited sequences for the
3DPCR products obtained at 88.7uC. In order to calculate the bias resulting from PCR close to the denaturation temperature, let’s assume that the
frequency of clones with 1–17 edited cytidines reflected sub optimal amplification, while the profile in Figure 4A is close to the true distribution. By
summing the number of clones with 1–17 and $18 edits for Figures 4A and 4B the estimated number with between 1–17 edits in Figure 4B is n,
where 79/n=7/300; n=3386. As the number of clones in Figure 4B with 1–17 edits is 284, 3DPCR underestimates the true frequency by a factor of
3386/284, or ,12. C) Bulk dinucleotide analysis of the 95uC sequences harbouring 1, 2–4 and $5G RA transitions reveals the CpC hallmark of A3G
editing. D & E) Clonal analysis reveals that editing was due to an APOBEC deaminase, approximately half being due to A3G. The smaller number of
sequences used (n=40) in these figures means that the values of 55% and 45% are less robust than for Figure 3C & 3D. F) 3DPCR amplification across
a 85–93uC gradient using either Taq or Pfu DNA polymerase, the latter fails to amplify DNA containing dU, the product of A3 deamination. Asterisks
indicate the PCR products cloned and sequenced. G) Mutation matrices of Pfu and Taq amplified HBV hypermutants given as percentages.
doi:10.1371/journal.ppat.1000928.g004
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leads to synthesis of the capsid monomer, HBcAg. Over the course
of a chronic infection, GRA mutations arise in the precore region,
particularly at residue G1896 and to a lesser extent G1897
resulting in the loss of HBeAg synthesis and HBeAg seroconver-
sion [53,54]. These mutations result in a W28Stop change. There
is no consensus as to whether this is due to A3 editing [20,25,55]
despite the fact that GRA transitions in a run of four Gs (4Cs on
the edited minus strand) are reminiscent of a hot spot for A3
deamination [21].
To explore this issue, a region spanning the precore region was
analyzed by PCR and 3DPCR from a HBV/A3G transfection
and patient #326. As can be seen from Figure 5A, G1896 was
indeed a hot spot for A3 editing (70–80% editing on the minus
strand) both in vivo and for the A3G transfection experiment.
Editing of the plus strand was also evident. This led us to analyze
the core region for samples #203, #318 and #372 at 85.5uC
(3DPCR) and 95uC (PCR). The data are summarized in Figure 5B.
A gradient of editing is apparent with G1896 and G1897
apparently hot spots for A3 editing. Focussing on mutations
identified at 95uC, which can be considered as relatively high
frequency events compared to those recovered by 3DPCR, they
overlap nicely with those reported in a number of previous studies
(Figure 5C) suggesting that A3 editing may well explain their
origin [54,55].
HBsAg mutants
The major viral surface antigen, HBsAg, is the basis of the
highly successful subunit vaccine. Vaccine escape mutants are
known, with a glycine to arginine (G145R) being the most frequent
substitution mapping to the common double loop ‘‘a’’ determinant
(residues 110–149, Figure 5D) [56,57]. A G145E substitution is
also known, as are a few other loop changes. The G145R mutant
also emerges among HBV-immunoglobulin (HBIg) treated
chronic carriers [58,59] and goes undetected by standard
diagnostic kits [60]. The local dinucleotide context associated
with the G145 substitutions (Figure 5D) are again reminiscent of
A3 editing. DNA spanning the ‘‘a’’ determinant was analyzed
using the two-step PCR/3DPCR approach. Not surprisingly
3DPCR recovered hypermutants from all 4 samples tested at a
restricting temperature of 85.5uC. The G145 codon was not a
hotspot in vivo. As expected, the degree of editing was lower for
genomes recovered at 95uC. Among sequences harbouring
substitutions in codon 145 most were hypermutants with the
Figure 5. A3 editing of the precore and HBsAg coding regions. A) Site specific frequency analysis of A3G editing in the precore region from a
tissue culture transfection experiment and from patient #326 recovered by 3DPCR at the restrictive temperature of 85.5uC. B) A selection of edited
precore sequences in vivo. C) Correlation of GRA and CRT edited sites observed from the 95uC amplifications of samples #203, #318, #326 and
#372 with those described from other studies with respect to the RNA stem loop structure implicit to DNA replication. D) Secondary structure of the
common ‘‘a’’ determinant of HBsAg. The frequent G145R substitution and the G145R variant are noted along with the corresponding codon changes.
E) A selection of A3 edited S region sequences bearing mutations in the G145 codon (standard PCR (95uC)). Such sequences represent ,10% of the
total.
doi:10.1371/journal.ppat.1000928.g005
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nied by other mutations (Figure 5E).
Discussion
The transcriptome data shows that numerous A3 genes are up
regulated in virus associated cirrhosis, notably A3B, A3C, A3G,
A3H and AICDA accompanied by a number of genes frequently up
regulated in inflammatory tissues. By contrast, for alcoholic
cirrhosis only two A3 genes (A3C and A3D) were significantly up
regulated. Using the dinucleotide context as a hallmark to identify
a posteriori the deaminase in vivo, A3G clearly emerges as a major
restriction factor for HBV replication in cirrhosis along with at
least one other A3 deaminase, which could be A3C (Figure 3C, D).
The degree of editing is every bit as extensive as in co-transfection
experiments using the powerful CMV-IE promoter in tissue
culture [16,21]. The up regulation of AICDA doesn’t impact HBV
editing in vivo despite the fact that AICDA shows itself to be a
potent editor of replicating HBV genomes (Figure 2). This
apparent dichotomy could be explained by the neogenesis of
lymphoid follicles harbouring AICDA
+ centroblasts, a feature
associated with chronic inflammation [61,62,63], or circulating
AICDA
+ B cells as has been described for chronic HCV infection
[64,65,66].
That A3G is the dominant A3 enzyme fits nicely with the fact
that of all the A3 genes, A3G is the most strongly up regulated by
interferon-a in primary hepatocytes [29]. Other reports show that
the gene is also sensitive to induction by interferon–c [28,30,34].
Pegylated interferon–a is used to treat a proportion of HBV
infected individuals and the present data may explain part of that
effect [67]. A recent report made a link between IFN-a treatment
and HBeAg seroconversion, although they concluded that the link
was tenuous given the low levels of editing in sera [25]. Although
they didn’t sequence precore DNA they used a 3DPCR approach.
As shown here, the technique tends to underestimate levels by
,10 fold (Figure 4). Accordingly hyperedited mutant frequencies
reported in that study [25] can be revised upwards to ,2–33%, in
excellent agreement with the present findings (,2–35%). Given
the strong impact of A3 deaminases on HBV replication in late
stage disease, where does the virus replicate, especially as it is not
known to encode an IFN or A3 antagonist? Some simple
possibilities could be interferon resistant or A3
low hepatocytes.
On a background of HBV+HCV double infection, HBV titres
are generally lower [68,69], as though HCV infection rendered
the liver an even more hostile environment for HBV. It might be
that the strong pro-inflammatory responses associated with HCV
immune responses induce A3 genes with their detrimental effect on
HBV. That the mean HBV cytidine deamination frequency was
higher from the double infection compared to the monoinfection is
the result expected if this hypothesis is correct (Figure 3B). As there
has been debate as to the importance of A3G alleles in HIV disease
(H186R [70]), it is possible that polymorphisms in the A3G gene
impact the outcome of HBV infection. Certainly the most striking
of all A3 polymorphisms, DA3B
2/2, doesn’t impact HBV disease
[22,71].
Given their ability to hypermutate DNA, A3 enzymes generate
complex mutant spectra, the vast majority probably being
deleterious. Even so, lightly A3 edited genomes predominated
(Figure 4A) while a small fraction resists degradation and are
repaired to standard DNA as the Pfu/Taq comparison shows
(Figure 4F). Thereafter selection will operate on the remaining
genomes. It would seem that IFN induced A3 editing may indeed
lead to the occasional emergence of variants, of which the precore
C1896T and/or C1897T and HBsAg G145R,E mutants are
tangible examples. In this respect, there are remarkable parallels
between some RNA viruses and IFN-a induction of the dsRNA
adenosine deaminase, ADAR-1L. Editing by this enzyme of
A1012 in the hepatitis D virus genome is essential to complete
replication [72,73]. Similarly, a handful of edited adenosine
residues allows escape of respiratory syncytial viruses from
monoclonal antibodies [74,75].
In conclusion, the cytokine storm associated with chronic
inflammatory responses to HBV and HCV clearly up regulates a
number of A3 genes with A3G clearly being a major restriction
factor for HBV. Could this also be a feature of other chronic
inflammatory syndromes or even autoimmune diseases? Although
the mutant spectrum resulting from A3 editing is highly
deleterious, a very small part, notably the lightly edited genomes
might help the virus evolve and even escape immune responses.
Materials and Methods
Patients, samples, RNA extraction, integrity and
amplification
Patients were predominantly males, the mean ages being 60
years (HBV), 63 years (HBV+HCV), 64 years (HCV) and 67 years
(alcoholic). All were negative for HIV. No patient was on
interferon therapy in the months prior surgery. The study was
approved by an Institutional Human Research Review Board
(RBM 2005–019) and by Institut Pasteur. Written informed
consent was obtained for each patient.
Forty-one cirrhotic samples as well as 4 normal livers were
dissected and directly frozen in liquid nitrogen after surgical
removal. Healthy samples represent tissue surrounding benign
tumours such as angioma or focal nodular hyperplasia. Total RNA
extraction was performed by a phenol-based method (Euromedex,
Souffelweyersheim, France). DNase treatment was performed on
10 mg of total RNA using a DNA-free kit (Ambion). The RNA
concentration and integrity were assessed using 100 ng of each
RNA isolate to perform a capillary gel electrophoresis analysis
(RNA 6000 Nano chip kit, Agilent Technologies, Palo Alto, CA) to
establish an RNA integrity index (RIN). All the samples had
acceptable quality, 86% with 7.0,RIN,10.0 and 14%,
4.1,RIN,6.9. Reverse transcription of 1 mg RNA was performed
in a final volume of 20 ml (High-Capacity cDNA Archive kit,
Applied Biosystems).
Real time quantitative PCR based gene expression
Messenger RNA were quantified by the TaqMan Low Density
Array (TLDA) technology (Applied Biosystems, Courtaboeuf,
France). Pre-designed hydrolysis probe and primer sets for target
genes were factory loaded into the 384 wells of TLDA configured
to contain duplicates per target gene (Table S2). Quantitative PCR
was performed using cDNA samples corresponding to 400 ng of
starting RNA and TaqMan Universal PCR Master Mix (Applied
Biosystems) for 48 target genes in duplicate. QPCR conditions
were one step of 94.5uC for 10 min. followed by 40 cycles at 97uC
for 30 sec. and 59.7uC for 1 min. on a 7900HT Micro Fluidic
Card instrument (Applied Biosystems).
For data analysis, gene expression values were determined using
the calculation of the relative quantitation (RQ) of target genes
normalized to a calibrator corresponding to 4 normal livers. RQ
calculation was performed using the {Delta}{Delta}CT method
using the geometric mean of three reference genes (TRIM44,
HMBS and LMF2). The three references genes were selected
among 12 constant genes arising from a previous array analysis of
70 HCC samples and 9 normal livers for which we applied the
algorithms described [76] in the geNorm manual available on the
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was performed according to the Minimum Information for
Publication of Quantitative Real-Time PCR Experiments (MIQE)
and redaction of the manuscript according to the RDML (Real-
Time PCR Data Markup Language) data standard (http://www.
rdml.org).
Molecular biology
The pCayw plasmid and all APOBEC and AICDA expression
plasmids have been previously described as have the cell lines and
transfection protocols [16,21]. Transfections were performed
independently in triplicate on Huh7 cells and supernatant HBsAg
was measured every day with the Monalisa HBsAg PLUS Kit (Bio-
Rad). 3DPCR [50] was performed on a Eppendorf gradient
Mastercycler S programmed to generate a 4–12uC gradient in the
denaturation temperature. A fragment of the X region was
amplified by employing a nested procedure. The first-round
primers were: 59Xout: 59CGCAAATATACATCGTATCCAT
and 39Xout: AAGAGTYYTYTTATGTAAGACYTT, where Y is
T,C and R is A,G. First PCR, conditions were: 5 min 95uC then
(30 sec, 95uC; 30 sec, 60uC; 1 min, 72uC) 635. Nested PCR was
performed with 1/50 of the first round, primers were: 59Xin:
ATGGCTGCTARGCTGTGCTGCCAA and 39Xin: AAGTG-
CACACGGTYYGGCAGAT, amplification conditions were:
5 min (82–93uC), then (1 min, 82–93uC; 30 sec, 60uC; 1 min,
72uC) 635 then at 10 min 72uC.
The precore amplification was performed as following, first
PCR, conditions were: 5 min 95uC then (30 sec, 95uC; 30 sec,
55uC; 1 min, 72uC) 635 with primers 59PreCout: GTACTAG-
GAGGCTGTAGGCATA and 39PreCout: 59 AGAGCT-
GAGGCGGTATCTAGAA. Nested PCR was performed with
1/50 of the first round, conditions were: 5 min (82–93uC), then
(1 min, 82–93uC; 30 sec, 55uC; 1 min, 72uC)635, then 10 min at
72uC and primers were: 59PreCin: TAAATTGGTCTGCGCAC-
CAGCA and 39PreCin: GATCTCGTACTGAAGGAAAGAA.
Amplification of the HBsAg was performed with a nested
procedure, first PCR conditions were: 5 min 95uC then (30 sec,
95uC; 30 sec, 60uC; 1 min, 72uC) 635, primers were: 59HBsout:
CGGCGTTTTATCATCTTCCTCTTCAT and 39HBsout: CA-
TCCATATAACTGAAAGCCAAACAGT. Nested PCR was
performed with 1/50 of the first round, conditions were 5 min
(82–93uC), then (1 min, 82–93uC; 30 sec, 60uC; 1 min, 72uC)635
then 10 min at 72uC with primers, 59HBsin: TCTTC-
ATCCTGCTGCTATGCCTCAT and 39HBsin: AAAGCCC-
TACGAACCACTGAACAAAT.
PCR and 3DPCR products were purified from agarose gels
(Qiaex II kit, Qiagen, France) and ligated into the TOPO TA
cloning vector (Invitrogen, France). The 88.7uC 3DPCR products
obtained from X gene amplification were chosen as experience
shows they provide a wide range of edited HBV genomes. While
products analyzed at lower temperatures are more edited, they
proved to be more homogeneous. Sequencing was outsourced to
Cogenics. All mutations were verified on the chromatogram.
Supporting Information
Figure S1 APOBEC3 transcriptome data normalized to mean
values for the four normal liver samples. Asterisks indicate
statistically significant up regulation: ** 0.01,p,0.001; * 0.05,
p,0.01.
Found at: doi:10.1371/journal.ppat.1000928.s001 (0.38 MB TIF)
Table S1 Brief description of the patients and genotype of the
accompanying tumour. CTNNB1=b-catenin gene.
Found at: doi:10.1371/journal.ppat.1000928.s002 (0.74 MB TIF)
Table S2 Statistically significant p values for gene up regulation
in cirrhotic tissue from four distinct groups compared to 4 healthy
liver controls. NS - not significant, p.0.05.
Found at: doi:10.1371/journal.ppat.1000928.s003 (0.82 MB TIF)
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